Results 141 to 150 of about 45,024 (296)

Novel Phenotypes of Acute Respiratory Failure and Differential Response to Awake Prone Positioning: A Multi‐Cohort Study

MedComm, Volume 7, Issue 7, July 2026.
Two novel clinical phenotypes in non‐intubated patients with acute respiratory failure were identified and validated across three independent cohorts. Phenotype 2 was associated with worse oxygenation, coagulation dysfunction, higher lactate, and significantly higher intubation and mortality rates within 28 days compared to Phenotype 1.
Nan Shi, Ruiqiang Zheng, Xufeng Chen, Huiying Zhao, Jun Jin, Changsong Wang, Shulin Xiang, Man Huang, Hongsheng Zhao, Yi Wang, Ruixuan Yu, Qin Sun, Hui Chen, Jianfeng Xie, Songqiao Liu, Yi Yang, Ling Liu, Haibo Qiu, the Chinese ARDS Research Network   +18 more
wiley   +1 more source

CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis

Journal of Multidisciplinary Healthcare
Fanchun Yang, Qingying Wang, Rui Ma, Fangzhen Deng, Jie Liu Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence: Jie Liu, Department of ...
Yang F, Wang Q, Ma R, Deng F, Liu J
doaj  

APTT Prolonged by Prekallikrein Deficiency [PDF]

Laboratory Medicine, 1998
Michael J. Sanfelippo, Anthony J. Cafaro, Winston N. Hollister   +2 more
openaire   +1 more source

A Low Serum Calcium‐to‐Potassium Ratio Predicts Postpartum Venous Thromboembolism Risk: Mediation by Hemoglobin and D‐Dimer in a Multicenter Cohort

MedComm, Volume 7, Issue 7, July 2026.
In a large multicenter cohort, a low serum calcium‐to‐potassium (Ca/K) ratio (< 0.55) in the third trimester was a novel risk factor for postpartum venous thromboembolism (VTE). This association was partly explained by concomitant variations in hemoglobin and D‐dimer levels, pointing to integrated management of electrolytes and anemia for postpartum ...
Qian Li, Guofu Zhang, Xiating Li, Huafang Wang, Jun Deng, Zhipeng Cheng, Fengjuan Fan, Shi Chen, De Li, Liang V. Tang, Yu Hu   +10 more
wiley   +1 more source

aPTT [PDF]

, 2019
openaire   +1 more source

Copolymers of Poly(Butylene Trans‐1,4‐Cyclohexanedicarboxylate)/Pripol as New Biomaterial Platform for Small Diameter Vascular Graft

Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.
Electrospun tubular scaffolds from novel PBCE‐based copolyesters and blends were designed as candidates for small‐diameter vascular grafts. They combine defect‐free architecture, blood‐compatible surfaces, and mechanical properties comparable to native vessels.
Edoardo Bondi, Gabriele Obino, Giulia Guidotti, Alberto Sensini, Martijn van Griensven, Antonio Junior Lepedda, Nadia Lotti, Lorenzo Moroni   +7 more
wiley   +1 more source

Engineered Heparinized GQDS/HPEI–Polyamide Membrane for Bilirubin Removal via One Step Anti Coagulation

Advanced Materials Interfaces, Volume 13, Issue 12, 23 June 2026.
A multifunctional heparinized polyamide membrane embedded with graphene quantum dots (GQDs) and hyperbranched polyethyleneimine (HPEI) is engineered for efficient bilirubin removal via a one‐step anticoagulation–adsorption process. The membrane demonstrates enhanced hemocompatibility, prolonged clotting times, and high bilirubin adsorption capacity ...
Abdur Rehman Mushtaq Ahmad, Maria Wasim, Aneela Sabir, Muhammad Shafiq, Syed Abdul Basit Shah, Maoz Maoz, Vanni Lughi   +6 more
wiley   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

Development of a Lupus Anticoagulant sensitive APTT Reagent with low heparin and high factor deficiency sensitivity

Activated Partial Thromboplastin Time (APTT) is a widely used assay to assess deficiencies in blood coagulation factors within the intrinsic pathway of coagulation. Nordic Biomarker produces and sells different products and one of them is an APTT reagent
Mathilda, Dahlén
core   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2293-2303, June 1, 2026.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source